ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024.

IF 2.9 4区医学 Q3 IMMUNOLOGY

Pediatric Infectious Disease Journal Pub Date : 2025-01-03 DOI:10.1097/INF.0000000000004715

Dale Carcione, Phoebe Spencer, Grace Pettigrew, Alan Leeb, Carla Drake-Brockman, Timothy Ford, Paul Effler

引用次数: 0

Abstract

Children receiving nirsevimab were texted a link to an online survey to monitor adverse events following immunization. Total of 4340 parents received the link, which 1195 (27.5%) responded. Forty-seven (11.4%) of 410 children who received nirsevimab alone and 230 (29.3%) of 785 children who received nirsevimab coadministered reported any reaction. No adverse events required in-patient care or had ongoing sequelae.

查看原文本刊更多论文

2024年4月至7月，西澳大利亚州对儿童施用nirseimab进行积极的上市后安全性监测。

接受nirsevimab的儿童收到了一份在线调查的链接，以监测免疫接种后的不良事件。共有4340名家长收到链接，其中1195名家长（27.5%）回复。410名儿童中有47名（11.4%）单独接受尼瑟维单抗治疗，785名儿童中有230名（29.3%）联合接受尼瑟维单抗治疗。没有不良事件需要住院治疗或有持续的后遗症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Infectious Disease Journal 医学-传染病学

CiteScore

6.30

自引率

2.80%

发文量

566

审稿时长

2-4 weeks

期刊介绍： The Pediatric Infectious Disease Journal® (PIDJ) is a complete, up-to-the-minute resource on infectious diseases in children. Through a mix of original studies, informative review articles, and unique case reports, PIDJ delivers the latest insights on combating disease in children — from state-of-the-art diagnostic techniques to the most effective drug therapies and other treatment protocols. It is a resource that can improve patient care and stimulate your personal research.